EGFR-directed Tyrosine Kinase Inhibitors (EGFR-TKIs), which have several generations, have been found effective in a type of lung cancer called non-small cell lung cancer (NSCLC) when compared to conventional, platinum-based chemotherapy. This evidence concerns the gene EGFR and lung carcinoma.